RECRUITING

The GBA Multimodal Study in Parkinson's Disease

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.

Official Title

Multimodal Molecular Imaging and Biometric Analysis in GBA-PD and Asymptomatic GBA-mutation Carriers

Quick Facts

Study Start:2019-05-01
Study Completion:2025-12-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04101968

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;
  2. * age 18 to 80 years.
  1. * co-occurrence of other neurological disorders;
  2. * implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);
  3. * severe claustrophobia;
  4. * intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);
  5. * ongoing treatment with cholinergic drugs

Contacts and Locations

Study Contact

Michele Matarazzo, MD
CONTACT
+1-604-822-7764
michele.matarazzo@ubc.ca

Principal Investigator

Michele Matarazzo, MD
PRINCIPAL_INVESTIGATOR
Pacific Parkinson's Research Centre | University of British Columbia
A. Jon Stoessl, CM, MD, FRCPC, FCAHS
PRINCIPAL_INVESTIGATOR
Pacific Parkinson's Research Centre | University of British Columbia

Study Locations (Sites)

Oregon Health & Science University
Portland, Oregon, 97239
United States
University of Washington
Seattle, Washington, 98108-1595
United States

Collaborators and Investigators

Sponsor: Pacific Parkinson's Research Centre

  • Michele Matarazzo, MD, PRINCIPAL_INVESTIGATOR, Pacific Parkinson's Research Centre | University of British Columbia
  • A. Jon Stoessl, CM, MD, FRCPC, FCAHS, PRINCIPAL_INVESTIGATOR, Pacific Parkinson's Research Centre | University of British Columbia

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-05-01
Study Completion Date2025-12-30

Study Record Updates

Study Start Date2019-05-01
Study Completion Date2025-12-30

Terms related to this study

Keywords Provided by Researchers

  • Parkinson

Additional Relevant MeSH Terms

  • Parkinson Disease
  • GBA Gene Mutation
  • Gaucher Disease